ArticleBreast cancer (Tokyo, Japan)2026
Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Transition from Parenteral to Subcutaneous Application of Systemic Oncological Therapy for Treating Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFixed-dose subcutaneous (SC) trastuzumab and pertuzumab (HP) (Phesgo®) offers a clinically non-inferior alternative to intravenous (IV) administration for HER2-positive breast cancer, with potential advantages in treatment efficiency. However, real-world evidence on its impact on healthcare workflow and frontline staff remains limited.
methodsWe conducted a single-center, mixed-methods evaluation comparing SC Phesgo® with conventional IV HP in the perioperative setting. Outcomes included patient treatment time, institutional reimbursement, and the operational burden on nurses and pharmacists, assessed through structured surveys, time-motion observations, and administrative records.
resultsPhesgo® reduced active treatment and clinic visit times by up to 96% and 53%, respectively. Cumulative chemotherapy suite time decreased by 332 h over eight months, indicating a potential for resource reallocation. Nurses and pharmacists reported reduced task complexity and improved workflow satisfaction, particularly during monotherapy. .Although combination regimens introduced procedural complexity, professional motivation remained stable. While SC administration is not eligible for chemotherapy-specific reimbursement add-ons in Japan, efficiency gains may partially offset revenue loss. Patient out-of-pocked costs increased slightly in lower-weight individuals but remained modest overall.
conclusionsPhasgo® improves both patient time burden and staff workflow efficiency, supporting more sustainable and patient-centered delivery of HER2-targeted therapy. These findings highlight the broader system-level value of fixed-dose SC regimens in high-volume oncology settings under real-world conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.